Insider Trading History of Robinson Chandler

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Robinson Chandler since 2021. This trader's CIK number is 1727334. At the time of last reporting, Robinson Chandler was the Chief Executive Officer of Monopar Therapeutics. (stock ticker symbol MNPR). Also see all insider trading activities at Monopar Therapeutics.


Yearly summary of insider trading at Monopar Therapeutics (MNPR) by Robinson Chandler

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2025 MNPR 0 $0 0 $0 23,452 $0
2024 MNPR 0 $0 0 $0 85,043 $0
2023 MNPR 0 $0 0 $0 114,694 $0
2022 MNPR 0 $0 0 $0 52,399 $0
2021 MNPR 0 $0 0 $0 18,548 $0


Insider trading of Monopar Therapeutics (MNPR) by Robinson Chandler

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2025-06-30 MNPR Option Ex 13,344 .00 0
2025-03-31 MNPR Option Ex 4,106 .00 0
2025-03-04 MNPR Option Ex 6,002 .00 0
2024-09-30 MNPR Option Ex 4,895 .00 0
2024-06-30 MNPR Option Ex 24,476 .00 0
2024-03-31 MNPR Option Ex 24,474 .00 0
2023-12-31 MNPR Option Ex 24,474 .00 0
2024-01-01 MNPR Option Ex 6,724 .00 0
2023-09-30 MNPR Option Ex 24,474 .00 0
2023-06-30 MNPR Option Ex 35,039 .00 0
2023-03-31 MNPR Option Ex 13,911 .00 0
2023-01-01 MNPR Option Ex 6,723 .00 0
2022-12-31 MNPR Option Ex 13,912 .00 0
2023-01-01 MNPR Option Ex 6,723 .00 0
2022-12-31 MNPR Option Ex 13,912 .00 0
2022-09-30 MNPR Option Ex 13,911 .00 0
2022-06-30 MNPR Option Ex 23,882 .00 0
2022-03-31 MNPR Option Ex 3,941 .00 0
2022-01-01 MNPR Option Ex 6,724 .00 0
2021-12-31 MNPR Option Ex 3,941 .00 0
2021-09-30 MNPR Option Ex 3,941 .00 0
2021-06-30 MNPR Option Ex 7,883 .00 0
2021-01-01 MNPR Option Ex 6,724 .00 0

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Robinson Chandler (Chief Executive Officer of Monopar Therapeutics at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.